Literature DB >> 15729251

The effect on porcine bile duct of a metallic stent covered with a paclitaxel-incorporated membrane.

Dong Ki Lee, Hyun Soo Kim, Kyung-Sik Kim, Woo Jung Lee, Ho Keun Kim, Young Hyun Won, Young Ro Byun, Moon Young Kim, Soon Koo Baik, Sang Ok Kwon.   

Abstract

BACKGROUND: Biliary metallic stents are covered with a membrane to prevent tumor ingrowth and to prolong patency. The only function of these stents is to promote biliary drainage; they have no antitumor effect.
METHODS: A metallic stent was developed that is covered with a paclitaxel-incorporated membrane. The metallic stents were coated with one of 3 concentrations of paclitaxel (0, 10, and 20 % wt/v) and polyurethane. A stent with each concentration was surgically inserted in the bile duct of two pigs. Four weeks after insertion, the segment of bile duct containing the stent was examined histologically. To determine the efficacy of the drug release, stents were placed in phosphate buffered saline solution for 6 weeks, and the amount of paclitaxel released was measured by high-performance liquid chromatography.
RESULTS: The histologic changes in the pig biliary epithelium were acceptable with respect to safety and included inflammatory cell infiltration and fibrous reactions. The changes corresponded to the amount of paclitaxel incorporated within the stent in contact with the bile duct. Epithelial denudation, mucin hypersecretion, and epithelial metaplasia were noted in the bile ducts that were in contact with stents containing 20 % wt/v paclitaxel. Transmural necrosis and perforation were not observed in any animal. In the in vitro experiment, the amounts of paclitaxel released over 1 week and over 6 weeks were similar, regardless of the concentration of paclitaxel incorporated in the stent. The stent with 10% (wt/v) paclitaxel in the covering membrane was found to be better than that with 20 % (wt/v) with respect to histologic changes and the effectiveness of drug release.
CONCLUSIONS: A paclitaxel-incorporated metallic stent could serve as a basis for the development of a new and safe treatment modality for malignant biliary obstruction. Clinical trials of this stent with other adjuvant therapy are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15729251     DOI: 10.1016/s0016-5107(04)02570-2

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  25 in total

Review 1.  Drug eluting biliary stents to decrease stent failure rates: A review of the literature.

Authors:  Joseph Shatzel; Jisoo Kim; Kartik Sampath; Sharjeel Syed; Jennifer Saad; Zilla H Hussain; Kabir Mody; J Marc Pipas; Stuart Gordon; Timothy Gardner; Richard I Rothstein
Journal:  World J Gastrointest Endosc       Date:  2016-01-25

2.  Antitumor effect of the paclitaxel-eluting membrane in a mouse model.

Authors:  Jin-Seok Park; Seok Jeong; Don Haeng Lee; Jin Hee Maeng; In Suh Park; Sangsoo Park
Journal:  Oncol Lett       Date:  2018-07-17       Impact factor: 2.967

3.  Drug-eluting stents in malignant biliary obstruction: where do we stand?

Authors:  Tilak Shah
Journal:  Dig Dis Sci       Date:  2013-03       Impact factor: 3.199

4.  A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.

Authors:  Laura Indolfi; Matteo Ligorio; David T Ting; Kristina Xega; Abraham R Tzafriri; Francesca Bersani; Nicola Aceto; Vishal Thapar; Bryan C Fuchs; Vikram Deshpande; Aaron B Baker; Cristina R Ferrone; Daniel A Haber; Robert Langer; Jeffrey W Clark; Elazer R Edelman
Journal:  Biomaterials       Date:  2016-03-31       Impact factor: 12.479

5.  Gastrointestinal stent update.

Authors:  Sung-Gwon Kang
Journal:  Gut Liver       Date:  2010-09-10       Impact factor: 4.519

6.  Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts.

Authors:  Ho-Soon Choi; Christopher E Savard; Jae-Woon Choi; Rahul Kuver; Sum P Lee
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

7.  Efficacy of a metallic stent covered with a paclitaxel-incorporated membrane versus a covered metal stent for malignant biliary obstruction: a prospective comparative study.

Authors:  Sung Ill Jang; Jie-Hyun Kim; Jung Whan You; Kwangwon Rhee; Se Joon Lee; Ho Gak Kim; Jimin Han; Im Hee Shin; Sang-Heum Park; Dong Ki Lee
Journal:  Dig Dis Sci       Date:  2012-11-21       Impact factor: 3.199

Review 8.  Managing malignant biliary obstruction in pancreas cancer: choosing the appropriate strategy.

Authors:  Brian R Boulay; Mayur Parepally
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

9.  Future developments in biliary stenting.

Authors:  Clark D Hair; Divyesh V Sejpal
Journal:  Clin Exp Gastroenterol       Date:  2013-06-24

10.  The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma.

Authors:  Vegard Tjomsland; Lina Niklasson; Per Sandström; Kurt Borch; Henrik Druid; Charlotte Bratthäll; Davorka Messmer; Marie Larsson; Anna Spångeus
Journal:  Clin Dev Immunol       Date:  2011-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.